Persimmon leaf extract in dyslipidemia: a systematic review and meta-analysis
Frontiers in Pharmacology · 15.09.2025 · 16
DOI: 10.3389/fphar.2025.1572678 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.09.2025. Verfasst von Chenxuan Dong und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
This study aims to evaluate the effects of the combined application of Diospyros kaki Thunb. [Ebenaceae; Kaki folium ] (Persimmon leaf) extract on lipid profiles in adults and to explore its potential role in preventing and treating lipid disorders and associated diseases, including common comorbidities such as cardiovascular and cerebrovascular diseases, as well as medication-induced dyslipidemia.
Methods
From the inception of the database to 1 November 2024, we retrieved randomized controlled trials (RCTs) from eight English and Chinese databases.
Results
A total of 704 articles were retrieved, from which 16 studies were selected for inclusion in the systematic review and meta-analysis. These studies encompassed 1,572 patients, with 790 assigned to the treatment group and 782 to the control group. Among the dyslipidemia patients included in the study, the most common comorbidities were coronary artery disease, hypertension, ischemic cerebrovascular disease, and dyslipidemia induced by olanzapine, among others. Compared with the control group, the use of combined Persimmon leaf extract (PLE) significantly reduced total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, while demonstrating a certain degree of improvement in high-density lipoprotein cholesterol (HDL-C) levels.
Conclusion
PLE has been shown to be effective in improving blood lipid profiles in patients, suggesting its potential for widespread clinical application. However, the significant heterogeneity observed across existing studies, coupled with the frequent occurrence of methodological flaws, emphasizes the need for well-designed clinical trials with large sample sizes and extended follow-up periods. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=562090 , identifier CRD42024562090.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
- EBM Office, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
- Department of Cardiology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
- Department of Pathology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
- Institute of Clinical Basic Medicine of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
- President's Office, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Zitieren
APA
Dong, C., Chang, T., Wang, X., Zhou, L., Wang, L., Wang, X., Sun, Y., Liao, X., Cui, Y., & Guo, J. (2025). Persimmon leaf extract in dyslipidemia: a systematic review and meta-analysis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1572678
Vancouver
Dong C, Chang T, Wang X, Zhou L, Wang L, Wang X, et al. Persimmon leaf extract in dyslipidemia: a systematic review and meta-analysis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1572678
BibTeX
@article{Dong2025,
author = {Dong, Chenxuan and Chang, Tianying and Wang, Xiaoli and Zhou, Lei and Wang, Lisha and Wang, Xiaodan and Sun, Yu and Liao, Xing and Cui, Yingzi and Guo, Jiajuan},
title = {Persimmon leaf extract in dyslipidemia: a systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1572678}
}
EUVIMED